ARTICLE | Company News
ChemoCentryx, Vifor Fresenius expand CCX140, avocapan deal to include China
June 15, 2018 7:30 PM UTC
ChemoCentryx Inc. (NASDAQ:CCXI) granted Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive rights to commercialize avacopan (CCX168) and CCX140 in China under the second expansion of a 2016 deal. Vifor Fresenius gained exclusive commercialization rights outside the U.S. and China to avacopan under the original deal, which the partners expanded the same year to include CCX140 (see BioCentury, Dec. 30, 2016).
ChemoCentryx will receive $21.5 million from Vifor up front for the Chinese rights and is eligible for royalties in the teens and mid-twenties...